Status:
COMPLETED
CGM Use in COVID19 Patients (Infection With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2))
Lead Sponsor:
Mayo Clinic
Conditions:
Diabetes Mellitus
Covid19
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
The purpose of this research is to determine if CGM (continuous glucose monitors) used in the hospital in patients with COVID-19 and diabetes treated with insulin will be as accurate as point of care ...
Detailed Description
Study participation involves placement of a continuous glucose monitor (CGM) on the abdomen of hospitalized patients who have a diagnosis of COVID19. The CGM will measure glucose levels every 5 minute...
Eligibility Criteria
Inclusion
- Patients 18 years or older.
- Patients with diagnosis of COVID-19 respiratory infection.
- Patient with recent positive SARS-COV2 infection and still positive polymerase chain reaction (PCR) admitted of non-respiratory diagnoses.
- Diagnosis of diabetes mellitus type 1 or type 2.
- Diagnosis of medication (steroid) induced hyperglycemia (persistent glucose more than 180 mg/dl).
- Taking insulin either SQ or IV.
Exclusion
- Patient in shock.
- Patient intubated on mechanical ventilation.
- Patient placed on Extracorporeal membrane oxygenation (ECMO).
- Patient taking hydroxyurea.
- Patient taking more than 4g of acetaminophen in 24 hours or more than 1g acetaminophen in 6 hours.
- Pregnant or nursing female patients.
- Patients with skin lesions at the application site that may interfere with placement of the sensor.
- Patients with known allergy to medical grade adhesive.
Key Trial Info
Start Date :
March 3 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 24 2022
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT04756141
Start Date
March 3 2021
End Date
August 24 2022
Last Update
August 4 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Mayo Clinic in Florida
Jacksonville, Florida, United States, 32224